ArticleDiscover oncology2025
Gut Escherichia coli promotes lung cancer by increasing circulating STAMBP production.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Intratumoral microbiota and metabolites: dual roles in cancer progression and therapeutic opportunities.Cell communication and signaling : CCS · 2026Review
- Targeting gut microbiota and metabolites in cancer radiotherapy.Clinical and translational medicine · 2025Review
- Exploring Gut Microbe-Host Genes in Postpartum Depression: Mendelian Randomization and Transcriptomic Analysis.International journal of women's health · 2025Article
- Lung cancer and the Gut-microbiota-lung Axis: emerging evidence and potential clinical implications.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExcessive abundance of gut pathogens and inflammatory lung damage are potential risk factors for lung cancer. Nevertheless, the exact function of inflammatory proteins in mediating the nexus between gut microbiota and lung cancer remains elusive.
methodsWe first executed Mendelian randomization analysis with the inverse variance weighting method as the primary method, followed by a sensitivity analysis of the results. Finally, we carried out in vitro experiments and database analyses to corroborate our conclusions.
resultsAfter multiple tests, we identified that the gut genus Parasutterella and species Escherichia coli (E. coli) were tied a heightened risk of lung cancer, while Bacteroides salyersiae was a protective factor against lung cancer. Circulating STAM-binding protein (STAMBP) and C-C Motif Chemokine Ligand 23 were considered potential risk factors for lung cancer. In vitro experimental results indicated that the E. coli supernatant significantly induced lung cancer cell proliferation and cell cycle transition but suppressed cell apoptosis. Mechanistically, E. coli increases the production of STAMBP to promote lung cancer progression.
conclusionsOur results indicated that gut E. coli can potentially increase STAMBP secretion, thereby promoting lung cancer progression. This research delivers a new viewpoint for analyzing the carcinogenic mechanism of E. coli as well as the subsequent prevention and management of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.